BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Aspirin
,
rs2476601
,
CXCL2
,
G-protein-coupled receptor binding
,
Obesity
,
Prostate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
tandutinib
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
NR1D1
FAM111A
Ugt2b37
RRM2
USP2
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
BERENJENO_TRANSFORMED_BY_RHOA_UP
heterocyclic compound binding
regulation of nitrogen compound metabolic process
FISCHER_DREAM_TARGETS
organic cyclic compound binding
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Livers of rat exposed to variety of hepatotoxic compounds
Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Affymetrix]
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Affymetrix]
Explore Curated Studies Results
Literature
Most Relevant Literature
Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib usi…
LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic …
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor rec…
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug…
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ